1
|
Li M, Luo A, Xu W, Wang H, Qiu Y, Xiao Z, Cui K. A Visual Raman Nano-Delivery System Based on Thiophene Polymer for Microtumor Detection. Pharmaceutics 2024; 16:655. [PMID: 38794317 PMCID: PMC11125006 DOI: 10.3390/pharmaceutics16050655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Revised: 05/09/2024] [Accepted: 05/11/2024] [Indexed: 05/26/2024] Open
Abstract
A visual Raman nano-delivery system (NS) is a widely used technique for the visualization and diagnosis of tumors and various biological processes. Thiophene-based organic polymers exhibit excellent biocompatibility, making them promising candidates for development as a visual Raman NS. However, materials based on thiophene face limitations due to their absorption spectra not matching with NIR (near-infrared) excitation light, which makes it difficult to achieve enhanced Raman properties and also introduces potential fluorescence interference. In this study, we introduce a donor-acceptor (D-A)-structured thiophene-based polymer, PBDB-T. Due to the D-A molecular modulation, PBDB-T exhibits a narrow bandgap of Eg = 2.63 eV and a red-shifted absorption spectrum, with the absorption edge extending into the NIR region. Upon optimal excitation with 785 nm light, it achieves ultra-strong pre-resonant Raman enhancement while avoiding fluorescence interference. As an intrinsically sensitive visual Raman NS for in vivo imaging, the PBDB-T NS enables the diagnosis of microtumor regions with dimensions of 0.5 mm × 0.9 mm, and also successfully diagnoses deeper tumor tissues, with an in vivo circulation half-life of 14.5 h. This research unveils the potential application of PBDB-T as a NIR excited visual Raman NS for microtumor diagnosis, introducing a new platform for the advancement of "Visualized Drug Delivery Systems". Moreover, the aforementioned platform enables the development of a more diverse range of targeted visual drug delivery methods, which can be tailored to specific regions.
Collapse
Affiliation(s)
- Meng Li
- College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200233, China; (M.L.); (H.W.)
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Aoxiang Luo
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Wei Xu
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Haoze Wang
- College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200233, China; (M.L.); (H.W.)
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Yuanyuan Qiu
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Zeyu Xiao
- College of Chemistry and Materials Science, Shanghai Normal University, Shanghai 200233, China; (M.L.); (H.W.)
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| | - Kai Cui
- Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; (A.L.); (W.X.); (Y.Q.)
| |
Collapse
|
2
|
Zinc Imidazolate Metal–Organic Frameworks-8-Encapsulated Enzymes/Nanoenzymes for Biocatalytic and Biomedical Applications. Catal Letters 2022. [DOI: 10.1007/s10562-022-04140-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
3
|
Michallek F, Nakamura S, Ota H, Ogawa R, Shizuka T, Nakashima H, Wang YN, Ito T, Sakuma H, Dewey M, Kitagawa K. Fractal analysis of 4D dynamic myocardial stress-CT perfusion imaging differentiates micro- and macrovascular ischemia in a multi-center proof-of-concept study. Sci Rep 2022; 12:5085. [PMID: 35332236 PMCID: PMC8948301 DOI: 10.1038/s41598-022-09144-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 03/17/2022] [Indexed: 12/30/2022] Open
Abstract
Fractal analysis of dynamic, four-dimensional computed tomography myocardial perfusion (4D-CTP) imaging might have potential for noninvasive differentiation of microvascular ischemia and macrovascular coronary artery disease (CAD) using fractal dimension (FD) as quantitative parameter for perfusion complexity. This multi-center proof-of-concept study included 30 rigorously characterized patients from the AMPLIFiED trial with nonoverlapping and confirmed microvascular ischemia (nmicro = 10), macrovascular CAD (nmacro = 10), or normal myocardial perfusion (nnormal = 10) with invasive coronary angiography and fractional flow reserve (FFR) measurements as reference standard. Perfusion complexity was comparatively high in normal perfusion (FDnormal = 4.49, interquartile range [IQR]:4.46-4.53), moderately reduced in microvascular ischemia (FDmicro = 4.37, IQR:4.36-4.37), and strongly reduced in macrovascular CAD (FDmacro = 4.26, IQR:4.24-4.27), which allowed to differentiate both ischemia types, p < 0.001. Fractal analysis agreed excellently with perfusion state (κ = 0.96, AUC = 0.98), whereas myocardial blood flow (MBF) showed moderate agreement (κ = 0.77, AUC = 0.78). For detecting CAD patients, fractal analysis outperformed MBF estimation with sensitivity and specificity of 100% and 85% versus 100% and 25%, p = 0.02. In conclusion, fractal analysis of 4D-CTP allows to differentiate microvascular from macrovascular ischemia and improves detection of hemodynamically significant CAD in comparison to MBF estimation.
Collapse
Affiliation(s)
- Florian Michallek
- grid.6363.00000 0001 2218 4662Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany
| | - Satoshi Nakamura
- grid.260026.00000 0004 0372 555XDepartment of Radiology, Mie University Graduate School of Medicine, Mie, Japan
| | - Hideki Ota
- grid.69566.3a0000 0001 2248 6943Department of Advanced MRI Collaborative Research, Tohoku University Graduate School of Medicine, Miyagi, Japan
| | - Ryo Ogawa
- grid.459909.80000 0004 0640 6159Saiseikai Matsuyama Hospital, Matsuyama, Japan
| | | | - Hitoshi Nakashima
- grid.416799.4National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
| | - Yi-Ning Wang
- grid.413106.10000 0000 9889 6335Peking Union Medical College Hospital, Beijing, China
| | - Tatsuro Ito
- grid.31432.370000 0001 1092 3077Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hajime Sakuma
- grid.260026.00000 0004 0372 555XDepartment of Radiology, Mie University Graduate School of Medicine, Mie, Japan
| | - Marc Dewey
- grid.6363.00000 0001 2218 4662Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany ,grid.452396.f0000 0004 5937 5237DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Kakuya Kitagawa
- grid.260026.00000 0004 0372 555XDepartment of Advanced Diagnostic Imaging, Mie University Graduate School of Medicine, Mie, Japan
| |
Collapse
|
4
|
Sampson DM, Dubis AM, Chen FK, Zawadzki RJ, Sampson DD. Towards standardizing retinal optical coherence tomography angiography: a review. LIGHT, SCIENCE & APPLICATIONS 2022; 11:63. [PMID: 35304441 PMCID: PMC8933532 DOI: 10.1038/s41377-022-00740-9] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 02/01/2022] [Accepted: 02/14/2022] [Indexed: 05/11/2023]
Abstract
The visualization and assessment of retinal microvasculature are important in the study, diagnosis, monitoring, and guidance of treatment of ocular and systemic diseases. With the introduction of optical coherence tomography angiography (OCTA), it has become possible to visualize the retinal microvasculature volumetrically and without a contrast agent. Many lab-based and commercial clinical instruments, imaging protocols and data analysis methods and metrics, have been applied, often inconsistently, resulting in a confusing picture that represents a major barrier to progress in applying OCTA to reduce the burden of disease. Open data and software sharing, and cross-comparison and pooling of data from different studies are rare. These inabilities have impeded building the large databases of annotated OCTA images of healthy and diseased retinas that are necessary to study and define characteristics of specific conditions. This paper addresses the steps needed to standardize OCTA imaging of the human retina to address these limitations. Through review of the OCTA literature, we identify issues and inconsistencies and propose minimum standards for imaging protocols, data analysis methods, metrics, reporting of findings, and clinical practice and, where this is not possible, we identify areas that require further investigation. We hope that this paper will encourage the unification of imaging protocols in OCTA, promote transparency in the process of data collection, analysis, and reporting, and facilitate increasing the impact of OCTA on retinal healthcare delivery and life science investigations.
Collapse
Affiliation(s)
- Danuta M Sampson
- Surrey Biophotonics, Centre for Vision, Speech and Signal Processing and School of Biosciences and Medicine, The University of Surrey, Guildford, GU2 7XH, UK.
| | - Adam M Dubis
- NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Trust and UCL Institute of Ophthalmology, London, EC1V 2PD, UK
| | - Fred K Chen
- Centre for Ophthalmology and Visual Science (incorporating Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, 6009, Australia
- Department of Ophthalmology, Royal Perth Hospital, Perth, Western Australia, 6000, Australia
- Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, 3002, Australia
| | - Robert J Zawadzki
- Department of Ophthalmology & Vision Science, University of California Davis, Sacramento, CA, 95817, USA
| | - David D Sampson
- Surrey Biophotonics, Advanced Technology Institute, School of Physics and School of Biosciences and Medicine, University of Surrey, Guildford, Surrey, GU2 7XH, UK
| |
Collapse
|
5
|
Carles M, Fechter T, Radicioni G, Schimek-Jasch T, Adebahr S, Zamboglou C, Nicolay NH, Martí-Bonmatí L, Nestle U, Grosu AL, Baltas D, Mix M, Gkika E. FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. Cancers (Basel) 2021; 13:cancers13040814. [PMID: 33672052 PMCID: PMC7919471 DOI: 10.3390/cancers13040814] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 02/05/2021] [Accepted: 02/07/2021] [Indexed: 02/06/2023] Open
Abstract
Simple Summary In this study, we strive to identify clinically relevant image feature (IF) changes during chemoradiation in patients with non-small-cell lung cancer (NSCLC) to be able to predict tumor responses in an early stage of treatment. All patients underwent static (3D) and respiratory-gated 4D PET/CT scans before treatment and a 3D scan during or after treatment. Our proposed method rejects IF changes due to intrinsic variability such as noise, resolution and movement through breathing. The IF variability observed across 4D PET is employed as a patient individualized normalization factor to emphasize statistically relevant IF changes during treatment. Abstract The aim of this study is to identify clinically relevant image feature (IF) changes during chemoradiation and evaluate their efficacy in predicting treatment response. Patients with non-small-cell lung cancer (NSCLC) were enrolled in two prospective trials (STRIPE, PET-Plan). We evaluated 48 patients who underwent static (3D) and retrospectively-respiratory-gated 4D PET/CT scans before treatment and a 3D scan during or after treatment. Our proposed method rejects IF changes due to intrinsic variability. The IF variability observed across 4D PET is employed as a patient individualized normalization factor to emphasize statistically relevant IF changes during treatment. Predictions of overall survival (OS), local recurrence (LR) and distant metastasis (DM) were evaluated. From 135 IFs, only 17 satisfied the required criteria of being normally distributed across 4D PET and robust between 3D and 4D images. Changes during treatment in the area-under-the-curve of the cumulative standard-uptake-value histogram (δAUCCSH) within primary tumor discriminated (AUC = 0.87, Specificity = 0.78) patients with and without LR. The resulted prognostic model was validated with a different segmentation method (AUC = 0.83) and in a different patient cohort (AUC = 0.63). The quantification of tumor FDG heterogeneity by δAUCCSH during chemoradiation correlated with the incidence of local recurrence and might be recommended for monitoring treatment response in patients with NSCLC.
Collapse
Affiliation(s)
- Montserrat Carles
- Department of Radiation Oncology, Division of Medical Physics, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (T.F.); (D.B.)
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- La Fe Health Research Institute, Biomedical Imaging Research Group (GIBI230-PREBI) and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), 46026 Valencia, Spain;
- Correspondence:
| | - Tobias Fechter
- Department of Radiation Oncology, Division of Medical Physics, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (T.F.); (D.B.)
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
| | - Gianluca Radicioni
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Tanja Schimek-Jasch
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Sonja Adebahr
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Constantinos Zamboglou
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Nils H. Nicolay
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Luis Martí-Bonmatí
- La Fe Health Research Institute, Biomedical Imaging Research Group (GIBI230-PREBI) and Imaging La Fe Node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), 46026 Valencia, Spain;
| | - Ursula Nestle
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
- Department of Radiation Oncology, Kliniken Maria Hilf, GmbH Moenchengladbach, 41063 Moechengladbach, Germany
| | - Anca L. Grosu
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| | - Dimos Baltas
- Department of Radiation Oncology, Division of Medical Physics, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (T.F.); (D.B.)
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
| | - Michael Mix
- Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany;
| | - Eleni Gkika
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Freiburg of the German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (S.A.); (C.Z.); (N.H.N.); (U.N.); (A.L.G.); (E.G.)
- Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, 79106 Freiburg, Germany; (G.R.); (T.S.-J.)
| |
Collapse
|